Thalassaemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-Thalassemia

  NCT07884773· Khyber Medical University Peshawar· Source

• A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety of Luspatercept in subjects who have participated in other Luspatercept (ACE-536) clinical trials.

  2022-502498-40-00· Celgene Corp.· Source

• A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

  NCT06813924· Novo Nordisk A/S· Source

• A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

  NCT06609226· Novo Nordisk A/S· Source

• A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia

  NCT05664737· Bristol-Myers Squibb· Source

• Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

  NCT00061568· National Heart, Lung, and Blood Institute (NHLBI)· Source

• A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

  NCT05891249· Bristol-Myers Squibb· Source

• Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

  NCT02105766· National Heart, Lung, and Blood Institute (NHLBI)· Source

• Gene Therapy for Patients With Transfusion-Dependent β-Thalassemia

  NCT07721480· Prince of Wales Hospital, Shatin, Hong Kong· Source

• Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

  NCT04143724· Celgene· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Gene Expression Profiling 1
• Proteomics 3
• Magnetic Resonance Imaging 5
• Cohort Studies 2

See which targets of this disease your abstract mentions, and go to the people working on them.